Leo Wealth LLC Sells 376 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Leo Wealth LLC lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 37.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 635 shares of the biopharmaceutical company’s stock after selling 376 shares during the period. Leo Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $452,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp raised its holdings in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. International Assets Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after purchasing an additional 11,499 shares in the last quarter. Swiss National Bank boosted its position in shares of Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after buying an additional 2,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company’s stock worth $316,957,000 after buying an additional 3,866 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $710.00 on Friday. The stock has a 50-day moving average price of $716.62 and a 200 day moving average price of $913.59. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock has a market capitalization of $78.02 billion, a P/E ratio of 17.57, a P/E/G ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the business posted $11.86 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Wall Street Analysts Forecast Growth

REGN has been the topic of several research analyst reports. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Finally, Citigroup cut their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.